Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study - 20/04/21
, Thierry de Baere b, Alexandra Heurgué c, Karine Le Malicot d, t, Isabelle Ollivier-Hourmand e, Thierry Lecomte f, Hervé Perrier g, Julien Vergniol h, David Sefrioui i, Yves Rinaldi j, Julien Edeline k, Jean-Louis Jouve l, Christine Silvain m, Yves Becouarn n, Barbara Dauvois o, Mathieu Baconnier p, Maryline Debette-Gratien q, Gael Deplanque r, Sébastien Dharancy s, Côme Lepage l, t, Mohamed Hebbar afor the
PRODIGE 16 investigators Collaborators1
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 10 |
| Iconografia | 3 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | TACE+sunitinib in the 1st-line therapy was feasible in HCC. |
• | No bleeding complication observed in both arms. |
• | Compliance to sunitinib was acceptable. |
• | In the era of immunotherapy, TACE-combined therapies research is needed. |
Summary |
Background |
Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection.
Aims |
We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure.
Methods |
Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated.
Results |
No bleeding complication was reported. One and two liver failures were respectively observed in sunitinib and placebo patients. Compliance to sunitinib treatment was acceptable. Sunitinib dose reduction occurred in 37% of patients due to acute toxicity. Main grade 3–4 toxicities were: thrombocytopenia, neutropenia, increased bilirubin, increased ALT and asthenia. In the sunitinib group, the median PFS and OS were 9.05 [5.81;11.63] and 25.0 [13.5;36.8] months, respectively. In the placebo group, the median PFS and OS were 5.51 [4.14;7.79] and 20.5 [15.1;30.6] months, respectively.
Conclusions |
TACE plus sunitinib in the first-line therapy for patients with HCC not suitable for surgical resection was feasible.
ClinicalTrials.gov number |
NCT01164202.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Transarterial chemoembolization, Sunitinib, Hepatocellular carcinoma, Liver failure, Bleeding complications
Abbreviations : HCC, TACE, VEGF, PFS, OS, EASL, ITT, mITT, CI
Mappa
Vol 45 - N° 2
Articolo 101464- Marzo 2021 Ritorno al numero
Articolo precedente
- Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients
- Changyong Chen, Huaiming Qiu, Yuanhui Yao, Zishu Zhang, Cong Ma, Yilong Ma, Chang Zhao, Hua Xiang, Hui Zhao, Chuansheng Zheng, Bin Xiong, Haiping Li, Qingyun Long, Jun Zhou, Chao Luo, Hongyao Hu
- LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival
- Jianfeng Tian, Dengdi Hu
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?